Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients
NCT ID: NCT02863640
Last Updated: 2018-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
13 participants
OBSERVATIONAL
2015-12-14
2017-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The L-Dopa is an endogenous ligand of the GPR43 receptor, located on the RPE's cell's apical pole.
This receptor, via several intracellular mechanisms, regulates the cell's exosomal and endosomal pathways: it would appear that the L-DOPA, by stimulating this receptor, decreases significantly the RPE's exosome release.
The contents of the exosomes is still uncertain, however in addition to their signalization role, it seems they transport pro-inflammatory components, possibly helping the cellular recruitment due to the mononuclear phagocytic systems, particularly toxic for the photoreceptors.
The aim of this study is to validate the hypothesis stating that he L-DOPA would play a protective role against age related macular degeneration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA
NCT03415984
Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration
NCT06694272
The Impact of Two Strategies in the Monitoring of Exudative ARMD on the Visual Acuity (by OCT B Scan or OCT Angiography)
NCT02868086
Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02941263
Molecular Imaging Exploration of Ocular Angiogenic Activity and Evaluation of Its Interest in the Therapeutic Follow-up of Patients With AMD (Age-related Macular Degeneration)
NCT04005443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposed patients
Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
Color retinography
Optical coherence tomography
Fundus autofluorescence imaging
Non exposed patients
Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
Color retinography
Optical coherence tomography
Fundus autofluorescence imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Color retinography
Optical coherence tomography
Fundus autofluorescence imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parkinson's disease
Exclusion Criteria
* Patient under a measure of legal protection
* Absence of affiliation to social security or universal health coverage (CMU)
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martine MAUGET FAYSSE
Role: PRINCIPAL_INVESTIGATOR
Fondation Ophtalmologique A. de Rothschild
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondation Ophtalmologique A. de Rotchschild
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMT_2015_33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.